Cargando…

Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution

BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, Laird B, Jiang, Damian H S, Moodie, Kate, Mitchell, Catherine, Solomon, Benjamin, Parameswaran, Bimal Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314638/
https://www.ncbi.nlm.nih.gov/pubmed/28209203
http://dx.doi.org/10.1186/s40644-017-0109-5
_version_ 1782508556882280448
author Cameron, Laird B
Jiang, Damian H S
Moodie, Kate
Mitchell, Catherine
Solomon, Benjamin
Parameswaran, Bimal Kumar
author_facet Cameron, Laird B
Jiang, Damian H S
Moodie, Kate
Mitchell, Catherine
Solomon, Benjamin
Parameswaran, Bimal Kumar
author_sort Cameron, Laird B
collection PubMed
description BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature. METHODS: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who analysed the evolution of these lesions, particularly for pre-defined significant and complex changes. RESULTS: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was 23 mm (range 9 – 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in 12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely concerning for malignancy or abscess in 4/26 patients. CONCLUSION: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided.
format Online
Article
Text
id pubmed-5314638
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53146382017-02-24 Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution Cameron, Laird B Jiang, Damian H S Moodie, Kate Mitchell, Catherine Solomon, Benjamin Parameswaran, Bimal Kumar Cancer Imaging Research Article BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature. METHODS: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who analysed the evolution of these lesions, particularly for pre-defined significant and complex changes. RESULTS: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was 23 mm (range 9 – 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in 12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely concerning for malignancy or abscess in 4/26 patients. CONCLUSION: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided. BioMed Central 2017-02-16 /pmc/articles/PMC5314638/ /pubmed/28209203 http://dx.doi.org/10.1186/s40644-017-0109-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Cameron, Laird B
Jiang, Damian H S
Moodie, Kate
Mitchell, Catherine
Solomon, Benjamin
Parameswaran, Bimal Kumar
Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title_full Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title_fullStr Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title_full_unstemmed Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title_short Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
title_sort crizotinib associated renal cysts [carcs]: incidence and patterns of evolution
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314638/
https://www.ncbi.nlm.nih.gov/pubmed/28209203
http://dx.doi.org/10.1186/s40644-017-0109-5
work_keys_str_mv AT cameronlairdb crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution
AT jiangdamianhs crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution
AT moodiekate crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution
AT mitchellcatherine crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution
AT solomonbenjamin crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution
AT parameswaranbimalkumar crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution